...function. By year-end, IM Therapeutics expects to begin preclinical development of small molecule inhibitors of HLA-DQ2...
...N.Y. Tolerion Inc., Portola Valley, Calif. Virobay Inc., Menlo Park, Calif. Targets HLA-Human leukocyte antigen HLA-DQ2-Major histocompatibility complex class II DQ2...
...II DQ8 MHCI-Major histocompatibility complex class I Jaime de León, Staff Writer IMT-002 VBY-129 ImmunoMolecular Therapeutics LLC Virobay Inc. Cathepsin S (CTSS) Major histocompatibility complex class II DQ2 (HLA-DQ2) Major...

...to investigate a similar approach to treat additional autoimmune diseases including celiac disease, for which HLA-DQ2...
...LLC, Broomfield, Colo. University of Colorado School of Medicine, Aurora, Colo. Business: Endocrine/Metabolic Mary Romeo JDRF University of Colorado HLA-DQ2 Human...

...celiac disease, for which HLA-DQ2 has been identified as an immune recognition gene. Mary Romeo University of Colorado HLA-DQ2 Major...

...super donor type is homozygous at the five HLA loci: HLA-A1, HLA-B8, HLA-C7, HLA-DR17, and HLA-DQ2...
...histocompatibility complex class I C7 HLA-DR17 - Major histocompatibility complex class II DR17 HLA-DQ2 - Major histocompatibility complex class II DQ2...

...for a T cell response in the 80-90% of celiac disease patients who carry the major histocompatibility complex class II DQ2 (HLA-DQ2)...
...plans to start two trials to assess the safety and tolerability of the vaccine in HLA-DQ2-positive...
...T cell response using ImmusanT's diagnostic, which is in early validation testing. "Patients who are HLA-DQ2-positive...

...it is suitable for 80-90% of celiac disease patients who carry the immune recognition gene HLA-DQ2...